Nasdaq:US$14.85 (-0.31) | HKEX:HK$23.20 (-0.30) | AIM:£2.30 (+0.05)
搜索结果
上一篇文章   |   下一篇文章
公告及新闻稿, 肿瘤学 / 免疫学 | 2009-11-05

Successful Global Phase IIb Ulcerative Colitis Trial for HMPL-004: All Primary and Secondary Endpoints Achieved Hutchison MediPharma Proceeding with Development and Partnership Plans